Asthma Attacks in Children—Challenges and Opportunities

Asthma is the most common chronic disease of childhood worldwide, and is responsible for signifcant morbidity and mortality in children and young people (CYP). Given the inherent dangers of a child experiencing even a single asthma attack, it is essential to identify and manage modifable risk factors at every clinical opportunity. Following an attack, there is an opportunity to prevent future attacks by assessing compliance and optimizing asthma control. Careful questioning will allow physicians to identify asthma triggers, barriers to good asthma control, and health beliefs or socioeconomic obstacles that may have contributed to this attack. The vast majority of children with asthma can achieve good symptom control with appropriate use of low-dose inhaled corticosteroids.

Intelligent evaluation of the efficacy of smart stethoscope in monitoring childhood acute asthma exacerbation / 中华实用儿科临床杂志

Objective:To evaluate the effects of smart stethoscope on the monitoring childhood asthma exacerbation, so as to assist family management in childhood asthma.Methods:A prospective randomized controlled study was carried out.A total of 80 children with asthma who were treated at Department of Pediatric Respiratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and Shanghai Tonxin Pediatric Clinic from November 2020 to May 2021 were enrolled and randomly divided into a test group of 40 cases (used the smart stethoscope) and a control group of 40 cases(not used the smart stethoscope). Medical history data were collected.The control group received monthly routine follow-up, while the test group was followed up both routinely and by smart stethoscope.In the test group, hearing wheezing sound was regarded as asthma exacerbation, and in the control group, the asthma exacerbation was reported by the parents themselves.The frequency of asthma exacerbation, asthma control level and quality of life were compared between the two groups.The recognition, diagnosis, treatment and outcomes of acute asthma exacerbation in two groups of children were described and analyzed.Measurement data were analyzed by t test or Mann- Whitney U test.Numeration data were analyzed by χ2 test. Results:Respiratory sounds collected by smart stethoscope in the test group were assessed by 3 specialist physicians.There were 12 wheezing rales (42.86%), 1 moist rale (3.57%) and 1 rhonchi rale (3.57%). Besides, 12 files (42.86%) were difficult to distinguish, and 2 files (7.14%) induced inconsistent identification.The number of asthma exacerbation was 12 in the test group and 5 in the control group.In the test group, 12 were recognized by the smart stethoscope, and only 6 were recognized by the parents.Comparing the diagnosis and treatment measures between two groups, it was found that there were more children in the test group (38.1%) receiving home treatment through telemedicine than those in the control group (20.0%). Besides, there were less children (61.9%) in the test group receiving unplanned hospital treatment (including unplanned outpatient, emergency and hospitalization) than those in the control group (80.0%). There was no statistically significant difference between the two groups of children during acute asthma exacerbation ( χ2=4.67, P=0.097). Parents were satisfied with the common functions, convenience and stability of smart stethoscope. Conclusions:Smart stethoscope can acquire the respiratory sounds of children with asthma in real time, achieving timely detection, diagnosis and treatment of asthma exacerbation in children.What′s more, smart stethoscope reduces the incidence of unplanned hospital diagnosis and treatment, and assists parents with better family management of children asthma.

Guia Prático de Atualização no tratamento da exacerbação de asma na criança e no adolescente ­ Posicionamento conjunto da Associação Brasileira de Alergia e Imunologia e Sociedade Brasileira de Pediatria / Practical Update Guide on the treatment of asthma exacerbation in children and adolescents ­ Joint position of the Brazilian Association of Allergy and Immunology and the Brazilian Society of Pediatrics

Exacerbação aguda de asma é uma condição frequente na criança e no adolescente e uma das causas mais comuns de procura aos pronto atendimentos e de internações. Pode ocorrer em pacientes que ainda não foram diagnosticados como asmáticos, e mesmo naqueles cujo controle da doença não se encontre adequado. Reconhecer a exacerbação e iniciar seu tratamento desde o domicílio até o adequado manejo inicial em ambiente hospitalar é fundamental para evitar sua evolução para complicações que coloquem o paciente em risco de vida. O tratamento compreende o reconhecimento e tratamento da hipoxemia, da obstrução e do processo inflamatório, além de fornecer orientações na alta hospitalar e encaminhamentos para continuidade do tratamento.

Acute exacerbation of asthma is a frequent condition in children and adolescents and one of the most common causes of seeking emergency care and hospitalization. It can occur in patients who have not yet been diagnosed with asthma, and even in those whose disease control is not adequate. Recognizing the exacerbation and starting its treatment from home until proper initial management in a hospital environment is essential to avoid its evolution to complications that put the patient at risk of life. Treatment comprises the recognition and treatment of hypoxemia, obstruction, and the inflammatory process, in addition to providing guidance at hospital discharge and referrals for continued treatment.

Bronchial Thermoplasty in Patients with Severe Uncontrolled Asthma: First Korean Cases

Bronchial thermoplasty is a nonpharmacological treatment for severe asthma that delivers thermal energy to the bronchial walls and reduces hypertrophied smooth muscle mass. Previous studies have shown its efficacy and safety, resulting in approval from the Food and Drug Administration in 2010. In Korea, the first bronchial thermoplasty was carried out in 2014; 4 patients have undergone the procedure so far. This case series presents the medical history and treatment outcomes of these 4 patients. All patients presented with uncontrolled asthma despite optimal medical treatment. Bronchial thermoplasty was performed at the right lower lobe, left lower lobe, and both upper lobes in order at 3-week intervals. All procedures were performed under general anesthesia. Two patients had significant decreases in exacerbations and required a lower dose of inhaled corticosteroids after the procedure. One patient had slightly fewer exacerbations but failed to reduce the use of systemic corticosteroids. One patient had no change in symptoms. One limitation of bronchial thermoplasty is the difficulty of predicting clinical responders. However, since more therapeutic options are needed in the management of severe asthma, especially T2-low asthma, discussion with experts about the feasibility and necessity of bronchial thermoplasty will ensure the best possible care.

The Interplay between Host Immunity and Respiratory Viral Infection in Asthma Exacerbation

Asthma is one of the most common and chronic diseases characterized by multidimensional immune responses along with poor prognosis and severity. The heterogeneous nature of asthma may be attributed to a complex interplay between risk factors (either intrinsic or extrinsic) and specific pathogens such as respiratory viruses, and even bacteria. The intrinsic risk factors are highly correlated with asthma exacerbation in host, which may be mediated via genetic polymorphisms, enhanced airway epithelial lysis, apoptosis, and exaggerated viral replication in infected cells, resulting in reduced innate immune response and concomitant reduction of interferon (types I, II, and III) synthesis. The canonical features of allergic asthma include strong Th2-related inflammation, sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), eosinophilia, enhanced levels of Th2 cytokines, goblet cell hyperplasia, airway hyper-responsiveness, and airway remodeling. However, the NSAID-resistant non-Th2 asthma shows a characteristic neutrophilic influx, Th1/Th17 or even mixed (Th17-Th2) immune response and concurrent cytokine streams. Moreover, inhaled corticosteroid-resistant asthma may be associated with multifactorial innate and adaptive responses. In this review, we will discuss the findings of various in vivo and ex vivo models to establish the critical heterogenic asthmatic etiologies, host-pathogen relationships, humoral and cell-mediated immune responses, and subsequent mechanisms underlying asthma exacerbation triggered by respiratory viral infections.

Concentraciones de albúmina modificada por la isquemia en niños con asma: estudio piloto / Ischemia-modified albumin levels in children with asthma: a pilot study

Introducción. La albúmina modificada por la isquemia puede aumentar en el asma (IMA), estrés oxidativo y la inflamación. El objetivo fue evaluar las concentraciones de IMA en niños asmáticos durante períodos asintomáticos y de exacerbación. Población y métodos. Niños asmáticos y sanos en seguimiento (grupo de referencia). La gravedad de la exacerbación se evaluó mediante la Iniciativa global para el asma (GINA) y la puntuación del índice pulmonar modificado (MPIS). Se usaron pruebas intraepidérmicas y de proteína C reactiva para medir las concentraciones séricas de IMA durante la exacerbación y 4 semanas después del tratamiento. Resultados. Participaron 26 pacientes y 26 controles. Las concentraciones medias de IMA durante la exacerbación (0,45 ± 0,12 ABSU) y durante el período de estabilidad (0,41 ± 0,14 ABSU) fueron mayores que en los niños sanos (0,32 ± 0,08 ABSU): p= 0,001 y p= 0,005, respectivamente. No hubo diferencias en IMA al agrupar a los pacientes por tratamiento antiinflamatorio, infección de las vías respiratorias altas previa a la exacerbación, concentraciones de PCR o sensibilidad a las pruebas intraepidérmicas. Las concentraciones fueron más elevadas en los pacientes con exacerbación grave que leve/moderada (p= 0,009). La correlación entre IMA y la gravedad de la exacerbación (r: 0,498; p= 0,010) fue positiva. Conclusiones. Los niños asmáticos presentaron concentraciones de IMA más elevadas que el grupo de referencia, tanto en el período de estabilidad como durante la exacerbación. Hubo una relación positiva entre las concentraciones de IMA y la gravedad de la exacerbación.

Introduction: Hypoxia may occur in the severe exacerbations of asthma. Ischemia-modified albumin (IMA) may increase in ischemia, in addition to oxidative stress and inflammation. The aim was to evaluate IMA levels in children during the asthma exacerbation and the asymptomatic period. Populations and methods: Children with asthma who were followed up in our clinic were included and healthy children were selected as the control group. The severity of exacerbation was evaluated with Global Initiative for Asthma and Modified Pulmonary Index Score. Serum IMA levels were measured at the time of exacerbation and 4 weeks after treatment during asymptomatic period. Skin prick test and C reactive protein (CRP) levels were measured. Results: A total of 26 patients and 26 controls were included. Mean IMA level was 0.45+0.12 absorbance units -ABSU- during asthma exacerbation and 0.32+0.08 ABSU in the control group (p=0.001). Mean IMA levels (0.41+0.14 ABSU) during the stable period were higher than the control group (p=0.005). There was no difference in terms of IMA levels when patients were grouped according to anti-inflammatory treatment, upper respiratory tract infection before exacerbation, CRP levels or sensitivity of skin prick tests. However, IMA levels were higher in patients with severe asthma exacerbation (p=0.009) in comparison with mild/moderate exacerbation. Positive correlation was observed between IMA levels and severity of exacerbation (r: 0.498, p=0.010). Conclusions: Asthmatic children had higher IMA levels than the control group, both in stable and exacerbated asthma. There was a positive relationship between IMA levels and severity of asthma exacerbation.

Viral Infections and Associated Factors That Promote Acute Exacerbations of Asthma

Despite asthma being the most common chronic childhood ailment, there is still much to learn about the disease. Early childhood infections with well-known or emerging viruses can lay the pathophysiologic framework for asthma development and exacerbation later in life, which may be due partly to alteration of the airway microbiome. Once asthma is established, acute exacerbations are usually associated with infections with respiratory viruses, such as rhinoviruses (RVs). Once again, there are bidirectional interactions between viruses and airway bacteria that appear to influence the severity of illness and the likelihood of exacerbation. Studies employing recent advances in viral and bacterial identification analytic techniques will clarify these new concepts and may provide the basis for new treatments or prevention or respiratory infection-associated exacerbation. This paper is a review of the associations among respiratory viruses, bacteria, inflammatory mechanisms, and asthma exacerbation.

Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea

PURPOSE: Omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, has proved to be effective for the treatment of severe asthma. However, there is no direct evidence of effectiveness of omalizumab in Korean patients with severe asthma. We sought to evaluate the real-world effectiveness of omalizumab in Korean adult patients suffering from severe asthma and to identify predictors of favorable response. METHODS: A retrospective analysis of electrical medical records was performed on severe allergic asthmatic patients with omalizumab treatment group (OT group) for more than 6 months between March 2008 and February 2016. Propensity score matching was applied to define the standardized treatment control group (STC group) treated without omalizumab. Asthma-related outcomes were compared between the 2 groups, and analyzed before and after omalizumab use in the OT group. Responders to treatment were defined as patients showing >50% reduction in asthma exacerbations and/or systemic steroid requirement during the outcome period. RESULTS: One hundred twenty-four patients with severe asthma (62 in the OT group; 62 in the STC group) were enrolled in the study. Proportion of patients having the reduction of asthma exacerbation (53.2% vs 35.5%, P=0.015) and the rate of responders (67.7% vs 41.9%, P=0.007) were significantly higher in the OT group than in the STC group. Significant reductions were noted in asthma exacerbation (P=0.006), hospitalization (P=0.009), hospitalization days (P=0.006), systemic corticosteroid requirements (P=0.027), and sputum eosinophil count (P=0.031) in OT group compared with STC group. There were no significant differences in changes of forced expiratory volume in the 1 second (FEV1) levels between the 2 groups. No predictors of responders were found for omalizumab treatment. CONCLUSIONS: Omalizumab can reduce exacerbations/hospitalization/systemic steroid burst in Korean adult patients with severe asthma.

Genetic Signatures of Asthma Exacerbation

Asthma exacerbation (AE) usually denotes worsening of asthma symptoms that requires intense management to prevent further deterioration. AE has been reported to correlate with clinical and demographic factors, such as race, gender, and treatment compliance as well as environmental factors, such as viral infection, smoking, and air pollution. In addition, recent observations suggest that there are likely to be genetic factors specific to AE. Understanding genetic factors specific to AE is essential to develop therapy tailored for exacerbation-prone asthma. Here, we summarize the results of studies involving genetic risk factors for AE. To simplify and enhance understanding, we reviewed the studies according to the following categories: hypothesis-driven approaches, hypothesis-free approaches, gene-environment interactions, and pharmacogenetics.

Evaluación del uso de corticoides inhalados en altas dosis para el tratamiento de crisis asmática / Evaluation of the Use of High-dose Inhaled Corticosteroids for the Treatment of Acute Asthma

Introducción: El asma es una enfermedad heterogénea caracterizada por la inflamación crónica de la vía aérea. Se caracteriza por síntomas respiratorios como sibilancias, disnea, opresión en el pecho, tos que varía en el tiempo y en la intensidad, además de presentar limitación variable al flujo aéreo. Afecta del 1 al 18% de la población mundial. Existe evidencia que sugiere que los corticoides inhalados pueden mostrar efectos terapéuticos tempranos (< 3 h). Esta rápida respuesta se encontraría vinculada a un efecto tópico (vasoconstricción de la mucosa de la vía aérea), debido a la potenciación del efecto adrenérgico por modificación de los receptores post-sinápticos. Materiales y métodos: Se realizó un estudio prospectivo, aleatorizado, analítico, longitudinal de cohorte y experimental, en pacientes con crisis de asma atendidos en la guardia externa del Hospital de Rehabilitación Respiratoria María Ferrer. Resultados: Se evaluó a un total de 71 pacientes en un período de 10 meses, todos ingresaron por el servicio de guardia del Hospital de Rehabilitación Respiratoria María Ferrer y accedieron a participar del protocolo firmando un consentimiento informado. Ambos grupos presentaron un 63% de respuesta significativa (FEV1 > 60%) a los 30 minutos de iniciado el tratamiento (p: 0.72). Al fnal del protocolo (180 minutos), el grupo control (salbutamol + bromuro de ipratropio) presentó 3 pacientes que no lograron el objetivo del FEV1 > 60% a comparación de 2 pacientes en el grupo tratado con corticoides inhalados a altas dosis (P: 0.97). Conclusión: Actualmente el uso de corticoides inhalados a altas dosis en crisis de asma es una opción terapéutica para pacientes con crisis moderadas a severas. Nuestro estudio no obtuvo valores significativos que apoyen el uso de esta medicación para reducir la incidencia de internaciones o mejorar significativamente la función pulmonar.

Introduction: Asthma is a heterogeneous disease characterized by chronic inflammation of the airways. Its more common respiratory symptoms such as wheezing, breathlessness, chest tightness and cough vary in time and intensity, in addition to displaying variable airflow limitation. Asthma affects 1 to 18% of the world population. Evidence suggests that inhaled corticosteroids may show early therapeutic effects (<3 hours). This quick response would be linked to a local effect (vessel constriction of the airway mucosa) due to the potentiation of the adrenergic effect that modifies the postsynaptic receptors. Materials and methods: A prospective, randomized, analytical and experimental longitudinal cohort study in patients with acute asthma treated at the emergency services of the Respiratory Rehabilitation Hospital Maria Ferrer, Buenos Aires. Results: A total of 71 patients were evaluated over a period of 10 months who had agreed to participate in the study by signing an informed consent. Both the study and the control groups had a 63% significant response (FEV1> 60%) within 30 minutes of starting treatment (p = 0.72). At the end of the observation (180 minutes), three patients of the control group (Salbutamol + ipratropium bromide) did not achieve the objective of FEV1> 60% compared to 2 patients in the study group treated with high-dose inhaled corticosteroids (P group: 0.97). Conclusion: Currently the use of high-dose inhaled corticosteroids in asthma attack is a therapeutic option for patients with moderate to severe crisis. The results of our study do not provide significant evidence in support of the use of this medication to reduce the incidence of hospitalizations or improve the lung function.

Factors Associated with Emergency Department Revisits and Hospitalization Following Discharged Acute Asthma Exarcerbation

The objectives were to identify factors associated with early revisit of adult patients with acute asthma exarcebation discharged from the Emergency Department (ED). It was a retrospective cohort study with patients aged 12 years or more within a period of 1 month and who were treated for acute asthma and discharged from the ED of Sarawak General Hospital. A total of 397 patients fulfilled sampling criteria and out of this number, 13.9% had revisit to the ED within 2 weeks. In all of these revisit cases, 9.1% were actually admitted. Prescription rate of oral corticosteroid was found to be low (24.9%) and abscond rate was high (25.1%). Patients who absconded from the ED and their concurrent infection were associated with early ED revisit.

Analysis of etiological agents in children with asthma exacerbation in 2013 / 重庆医学

Objective To investigate the distribution of etiological agents in children with asthma exacerbation in Chongqing during 2013 .Methods Four hundred and forty seven cases of hospitalized children with asthma exacerbation in 2013 in Children′s Hospital of Chongqing Medical University were retrospectively analyzed in SPSS19 .0 software .Results Among the 447 children with asthma exacerbation ,the percentage of bacteria was 43 .8% ,streptococcus pneumonia(SP)(25 .5% ) was the most common bacteria .Among the 25 cases with bacteria culture of bronchoalveolar lavage ,the positive rate was 44 .0% ,and the difference to sputum culture was not significant (P>0 .05) .The positive rate of 7 common respiratory viruses was 27 .3% ,RSV accounted for 18 .8% ,and it was the most common virus .The virus infection rate was higher in the groups below one years old ,and compared each groups′virus detection rates ,the difference was significant (P< 0 .05) .The positive rate of mycoplasma pneumoniae was 23 .5% ,chlamydia pneumonia was not detected .Conclusion Asthma exacerbation in children is closely related to respiratory infec‐tion .Bacteria detection rate was high in all ages ,which suggests that bacterial infection is an important factor in asthma exacerbation that can′t be ignored .

Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy

PURPOSE: There have been few reports regarding the efficacy of antiasthmatics in older patients. To compare the efficacy of the addition of montelukast to low-dose inhaled budesonide (MON-400BUD) versus increasing the dose of inhaled steroid (800BUD) on asthma control in older asthmatics. METHODS: A randomized, open-label, parallel-designed trial was conducted for 12 weeks. The primary endpoint was the rate of patients who reached "well-controlled asthma status" after the 12-week treatment period. Additionally, asthma exacerbations, sputum inflammatory cells, asthma control test (ACT) and physical functioning scale (PFS), and adverse reactions were monitored. RESULTS: Twenty-four (36.9%) and 22 (34.9%) subjects in the MON-400BUD (n=65) and 800BUD (n=63) groups had well-controlled asthma at the end of the study, respectively. The numbers of asthma exacerbations requiring oral corticosteroid treatment (20 vs 9, respectively, P=0.036) and the development of sore throat (22 vs 11, respectively, P=0.045) were significantly higher in the 800BUD group than in the MON-400BUD group. Body mass index and changes in ACT, FEV1%, 6-min walk distance and PFS from baseline were all significant determinants for distinguishing subjects with well-controlled and partly controlled asthma from those with uncontrolled asthma (P<0.05) at the end of the study. CONCLUSIONS: The efficacy of 12-week treatment with MON-400BUD in older asthmatics was comparable to that of 800BUD on asthma control but associated with reduced frequency of asthma exacerbations requiring oral steroids and sore throat events. Changes in ACT and PFS can be useful predictors of asthma control status in older patients.

Relationship between sensitivity to dyspnea and fluctuating peak expiratory flow rate in the absence of asthma symptoms

BACKGROUND: Exacerbation of asthma has a negative impact on quality of life and increases the risk of fatal asthma. One of the known risk factors for patients with a history of near-fatal asthma is reduced sensitivity to dyspnea. OBJECTIVE: We aimed to identify patients with such risk before they experienced severe exacerbation of asthma. METHODS: We analyzed asthma symptoms and peak expiratory flow rate (PEFR) values of 53 patients recorded daily in a diary over a mean period of 274 days. Patients matched their symptoms to one of eight categories ranging in severity from 'absent' to 'severe attack'. We then analyzed the relationship between PEFR and asthma symptoms by dividing the PEFR value by the values of clinical parameters, including asthma symptom level.

The Determinant of the Severity Who was Hospitalized with Asthma-like Symptoms in Influenza A (H1N1) Season / 소아알레르기및호흡기학회지

PURPOSE: The aim of study was to identify the predictors of severe asthma exacerbation with influenza A (H1N1) infection so that intensive care could be initiated immediately. METHODS: Patients were diagnosed influenza A (H1N1), using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) from the nasal aspirates in St. Mary's Medical Center, Busan, Korea, between September, 2009 and February, 2010. Medical records were retrospectively reviewed to collect data. Data were analyzed in two groups by severity of asthma exacerbation. The groups were severe groups and mild-moderate. Statistical analysis was performed by SPSS ver. 12.0. RESULTS: A total of 1,054 children were diagnosed influenza A (H1N1) infection. Of 1,054, 318 (30.1%) were hospitalized. There were 200 boys (62.9%) and median age was 5.0 years (0.1 to 18.0 years). Among hospitalized, 25.2% (80/318) were diagnosed asthma exacerbation. Among 80 patients, 16 (20.0%) were severe group. and 64 (80.0%) were mild-moderate. High leukocyte counts, neutrophil counts, and C-reactive protein (P or =0.05) were not reliable predictors. CONCLUSION: Among who had influenza A (H1N1) infection with asthma-like symptoms, patients who had not been managed asthma before, had high leukocyte, neutrophil, and C-reactive protein in serum, are likely to progress severe asthma exacerbation.

Effect of air pollution on acute exacerbation of adult asthma in Seoul, Korea / 대한내과학회지

It has been well recognized that air pollution contributes to the development and exacerbation of asthma, especially in children and elderly. However, the impact of air pollution on the exacerbation of asthma in adult is not established, due to various approach methods including study design, geography and exposure period. Kim et al. studied it using case-crossover method in adult patients with exacerbating asthma visited multi-center emergency department in Seoul. Unlike to other studies, they suggested that the air pollution was not associated with the exacerbation of adult asthma. A large-scaled study including variable information such as economic status, aeroallergen, and infection will be helpful to clarify the impact of air pollution on asthma exacerbation in Korea.

Effectiveness of intravenous clarithromycin followed by oral clarithromycin in acute exacerbation of asthma with respiratory tract infection.

In addition to its antimicrobial activity, macrolides have an immunomodulatory effect that may be beneficial to patients with asthma. This quasi-experimental study aimed to determine the effect of intravenous clarithromycin followed by oral administration in 37 patients with acute exacerbations asthma caused by respiratory tract infection during January - December 2005. Patients with mild to moderate exacerbations of asthma with respiratory tract infection meeting the inclusion and exclusion criteria were given intravenous clarithromycin 2 x 500 mg/day for not more than 5 days and followed by oral clarithromycin 2 x 500 mg/day for 7 days. Outcome variables were improvement of clinical symptoms according to the asthma exacerbation score and peak expiratory flow rate (PEFR). After 10 days, treatment resulted significant improvement in total asthma exacerbation score and morning PEFR in 35 patients enrolled this project. Based on clinical improvement and laboratory findings, the number of days required for intravenous clarithromycin was less then 3 days for 21 subjects, 3-5 days in 14 subjects. The most common causative pathogens were S. β-haemolyticus and Streptococcus sp. It was concluded that clarithromycin improved clinical symptoms and PEFR in exacerbation of asthma caused by respiratory tract infection.

Association of Plasma Eotaxin with Asthma Exacerbation and Severity / 결핵

BACKGROUND: The eosinophil chemotactic and activating effects of eotaxin and the known association of eosinophils with asthma suggest that eotaxin expression is increased during an asthma attack. This study was aimed to determine whether the plasma eotaxin levels are higher in patients during as asthma attack and to correlate the eotaxin levels with the disease activity, severity and response to therapy. METHOD: A case-control study of the plasma eotaxin levels was performed in 100 patients with exacerbated asthma and 48 age-and sex-matched subjects with stable asthma. RESULTS: The plasma eotaxin levels were significantly higher in the 100 patients with exacerbated asthma (233±175 pg/ml) than in the 48 subjects with stable asthma(169±74 pg/ml). A tread toward higher eotaxin levels was observed in asthmatic subjects who were taking oral steroids (332±225 pg/ml) than in those who were not (214±159 pg/ml) and higher levels were found in those admitted to the hospital (275±212 pg/ml) than in those discharged after receiving only emergency treatment (190±115 pg/ml). The eotaxin levels inversely correlated with the FEV1 (r=-0.25, p<0.01). The eotaxin levels were higher in moderate persistent (323±256 pg/ml) and severe persistent asthmatics (276±170 pg/ml) than in mild intermittent asthmatics (160±60 pg/ml). CONCLUSION: Eotaxin expression is directly associated with asthma exacerbation, impaired pulmonary function and the disease severity.